The Just-In-Time (JIT) Core Usage Funding Program is designed to provide quick access to funding to use any of the JIT Cores for research advancing medical knowledge that can improve human health. The program provides support for investigators in obtaining final data that: Will be used for development of a clinical/translational proposal to be submitted for extramural funding; […]
Pre-configured panels are available for next day delivery Unique targets in the market: ADAM12, PAPP-A, CD66f (PSBG-1), HO-1 (Heme Oxygenase 1), and Beta-catenin Ask me about matching ProcartaPlex panels on our RNA multiplex platform (QuantiGene) Key Features of ProcartaPlex Immunoassays: Multianalyte detection with a large dynamic range All ProcartaPlex assays are individually tested for specificity […]
Rapidly detect SARS-CoV-2 coronavirus antibodies (immunoglobulins, IgG and IgM) or viral proteins in serum or plasma ProcartaPlex Human Coronavirus Ig Total 11-Plex Panel This Human SARS-CoV-2 Spike (trimer) ELISA kit enables the detection of anti-SARS-CoV-2 Ig antibodies in human serum with great sensitivity and specificity. Human SARS-CoV-2 Protein, Serology and Neutralizing Ab ELISAs Human SARS-CoV-2 ELISA […]
Measure Ig titers We offer a comprehensive menu of Invitrogen™ ELISA and ProcartaPlex™ assays for serological detection of immunoglobulins (Ig) in response to SARS-CoV-2 infection or vaccination. Fast, easy workfl ow—incubation times of 1.5 hr for ELISAs (Fig. 1) or 2.5 hr for ProcartaPlex assays High sensitivity and specifi city—developed and validated with PCR (+) […]
COVID-19 vaccination elicited antibody responses in nearly nine out of 10 people with weakened immune systems, although their responses were only about one-third as strong as those mounted by healthy people, according to a study by researchers at Washington University School of Medicine in St. Louis.
Vaccines likely induce strong, persistent immunity to COVID-19
This episode of ‘Show Me the Science’ details how School of Medicine scientists began working with the virus, ramping up research efforts while the rest of the world was shutting down
On June 12, 2020, the IML and the Shreiber Lab participated in Wear White for a Future. By wearing white together, we are standing for science and the search for immune-based cures. Wear White Day is critical part of June’s Cancer Immunotherapy Month awareness and education programs. #Immune2Cancer
A human antibody that protects mice against a wide range of lethal flu viruses could be the key to a universal vaccine and better treatments for severe flu disease, according to a new study from Washington University School of Medicine in St. Louis, Icahn School of Medicine at Mount Sinai in New York City, and […]
A new School of Medicine study indicates a way for cancer immunotherapy to spur a more robust immune response. Such knowledge could lead to the development of better cancer vaccines and more effective immunotherapy drugs.
Washington University School of Medicine in St. Louis has established a Division of Physician-Scientists to help nurture the career development of physicians who want to conduct scientific research. The new division will be headed by Wayne M. Yokoyama, MD, the Sam J. Levin and Audrey Loew Levin Professor of Arthritis Research.
On June 14, 2019, the Shreiber Lab participated in Wear White for a Future. By wearing white together, they are standing for science and the search for immune-based cures. Wear White Day is critical part of June’s Cancer Immunotherapy Month awareness and education programs. #Immune2Cancer
Chancellor Mark S. Wrighton lists Bob Schreiber’s work on immunological approaches to dealing with diseases, including cancer as an accomplishment that has made one of the biggest impact during his tenure.
Robert D. Schreiber, PhD, the Andrew M. and Jane M. Bursky Distinguished Professor of Pathology and Immunology at Washington University School of Medicine in St. Louis, has been elected a fellow of the American Association for Cancer Research (AACR) Academy.
Ali Ellebedy, PhD (an assistant professor of pathology and immunology and a researcher with the Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs) and colleagues will compare how people’s immune systems respond to the yellow-fever vaccine and the inactivated flu vaccine to better understand how vaccines elicit long-lasting immune responses. In contrast to the flu vaccine, the yellow-fever vaccine provides robust life-long immunity.
Immune-based therapies are becoming a reality for cancer care. A few short decades ago, cancer treatment consisted mainly of three pillars: surgery, radiation and chemotherapy. Although each has earned its place as a valuable option, more precise alternatives have long been the oncologist’s dream.
Michael S. Diamond, MD, PhD, an infectious diseases specialist at Washington University School of Medicine in St. Louis, has been chosen as the recipient of the American Society for Clinical Investigation’s 2019 Stanley J. Korsmeyer Award. He is being honored for his contributions to understanding the molecular basis of disease caused by globally emerging RNA viruses such as the Zika, West Nile and chikungunya viruses.
Neuroscientist Azad Bonni, MD, PhD, and virologist and immunologist Michael S. Diamond, MD, PhD, both of Washington University School of Medicine in St. Louis, have been elected to the National Academy of Medicine, a part of the National Academy of Sciences. Membership in the organization is one of the highest honors in the fields of health and medicine in the United States.
Radiation oncologist Carl J. DeSelm, MD, PhD, has been honored by the National Institutes of Health (NIH) for his visionary research to harness the immune system to fight cancer.
Norman E. “Ned” Sharpless, MD, newly named director of the National Cancer Institute of the National Institutes of Health (NIH), speaks at a town hall Tuesday, Feb. 27, on the Medical Campus. He visited the School of Medicine to attend and speak at the Bursky Center symposium and participate in a town hall.
Robert D. Schreiber, PhD, the Andrew M. and Jane M. Bursky Distinguished Professor at Washington University School of Medicine in St. Louis, has been named a co-recipient of the Balzan Prize for his groundbreaking work in immunology and melanoma research.
Gavin Dunn MD, PhD, a member of the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, focuses on glioblastoma, the most deadly form of brain cancer. He studies how the immune system recognizes brain cancer cells and how it can be harnessed to treat patients with glioblastoma.
Michael S. Diamond, MD, PhD, Robert D. Schreiber, PhD, and Wayne M. Yokoyama, MD, lead a team of investigators working to develop new immune-based therapies for cancer, infectious disease, autoimmunity and immunodeficiency in the newly named Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy at Washington University School of Medicine.
Andrew and Jane Bursky donated $10 million to Washington University for its research on using the immune system to fight diseases including cancer. The gift creates the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs and an endowed distinguished professorship for cancer immunologist Robert Schreiber, director of the center and an adviser to Vice President Joe Biden’s cancer moonshot project.